A compound having Structural Formula I ** Formula ** or a pharmaceutically acceptable salt thereof, in which: R 1 is -H, halo, -OH or -C 1-3 alkyl； m is an integer selected from zero (R3b is absent) and 1 (R3b is present)； n is an integer selected from 1 or 2； R2 is independently selected at each occurrence from -H,>； = O (oxo), -OH, -C1-3alkyl or -C1-3alkyl, with the proviso that when n is 2, then at least one R2 is - H； R3a is -H,>； = O, -C3-4 cycloalkyl or -C1-3alkyl optionally substituted with -OCH3 or 1 to 3 of -F, with the proviso that only one of R2 or R3a can be>； = O , R3b is - H or -C1-3alkyl, or R3b is absent when R3a is>； = O or when the discontinuous bond is a double bond or an aromatic bond； or R3a and R3b bind, together with the carbon to which both are attached, to form cyclopropyl or cyclobutyl； or when n is 1, R2 and R3a can be attached, together with the carbons to which each is attached, to form (1) a phenyl ring that is fused to the pyrrolidine ring, and m is zero, or (2) a cyclopropyl ring fused to the pyrrolidine ring, and m is 1； R4 is -H or>； = O； R5 is (a) -H, (b) halo, (c) -C1-3alkyl optionally substituted with -O-C1-3alkyl, (d) -C3-6cycloalkyl or (e) heterocycle optionally substituted with -alkyl C1-3 or halo； R6 is -H or -C1-3alkyl； R7a is -H or -C1-3alkyl optionally substituted with -OH, -OCH3 or 1 to 3 of -F； R7b is -H or -C1-3alkyl； or R7a and R7b bind, together with the carbon to which both are attached, to form C3-4 -cycloalkyl； R8 is -H, halo or -C1-3 alkyl； R9 is -H, -F, -OH, -C1-3alkyl, -CH2OH, -NH-R13 or ** Formula ** R10 is -H, halo, -CN, -C3-4cycloalkyl or -C1 -alkyl 3 optionally substituted with 1 to 3 of -F； or R9 is -O- and joins with R10 to represent -CH2-CH2-O-； R11 is -H, -CH2OH, -CH2OCH3 or -C1-3alkyl optionally substituted with 1 to 3 of -F； R12 is -H, -CH2OH, -CH2OCH3 or -C1-3alkyl optionally substituted with 1 to 3 of -F； or R11 and R12 are joined to represent -CH2-CH2-, -CH2-N (CH3) -CH2- or -CH2OCH2-； R13
